A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Davids MS, Brander DM, Alvarado Valero Y, Diefenbach CS, Egan DN, Dinner SN, Javidi-Sharifi N, Al Malki MM, Begna K, Bhatt VR, Abedin S, Cook R, Collins MC, Roleder C, Dominguez EC, Rajagopalan P, Wiley SE, Ghalie RG, Danilov AV.
Davids MS, et al. Among authors: abedin s.
Blood Adv. 2024 Dec 20:bloodadvances.2024014633. doi: 10.1182/bloodadvances.2024014633. Online ahead of print.
Blood Adv. 2024.
PMID: 39705540